Table 2.
Short‐Term Outcomes of Transcatheter Mitral Valve‐in‐Valve Replacement
| Study, YearREF | 30‐d Mortality | Stroke | Bleeding* | MVC | Device Thrombosis | Technical Success | LVOTO | Valve Embolization | ≥3+Residual MR |
|---|---|---|---|---|---|---|---|---|---|
| Yoon et al, 2019 (N=322) 35 | 6.2 | 2.3 | 4.6 | 1.6 | NA | 94.4 | 2.2 | 1.7 | 3.3 |
| Guerrero et al, 2019 (N=1326) 37 , * |
TS: 5.0 TA: 8.1 |
TS: 1.1 TA: 1.0 |
NA |
TS: 1.2 TA: 2.5 |
TS: 0.2 TA: 0.5 |
TS: 97.3 TA: 94.6 |
TS: 0.8 TA: 2.0 |
TS: 0.2 TA: 0.5 |
NA |
| Hu et al, 2018 (N=172) 30 | 7.5 | 3.2 | 8.7 | 0.0 | 3.2 | 97.1 | 0.0 | 5.3 | 5.5 |
| Urena et al, 2018 (N=34) 32 | 5.9 | 5.9 | 5.9 | 5.9 | 8.8 | 94.1 | 5.9 | 2.9 | 0.0 |
| Kamioka et al, 2018 (N=62) 31 | 3.2 | 0.0 | 6.5 | 1.6 | 1.9 | NA | 3.2 | NA | 3.8 |
| Yoon et al, 2017 (N=176) 36 | 5.7 | 2.3 | 2.3 | 1.7 | NA | 96.0 | 3.2 | 1.1 | 3.6 |
| Eleid et al, 2017 (N=60) 29 | 6.0 | 0.0 | 7.0 | 3.3 | 2.0 | 97.0 | 5.0 | 0.0 | 0.0 |
| Eleid et al, 2016 (N=33) 28 | 8.0 | 0.0 | 8.0 | 0.0 | 2.0 | 93.9 | 4.0 | 6.0 | 0.0 |
| Ye et al, 2015 (N=31) 34 | 1.0 | 3.2 | 3.2 | 0.0 | 0.0 | 98.6 | NA | 0.0 | 5.0 |
| Cheung et al, 2013 (N=23) 27 | 0.0 | 4.4 | 0.0 | NA | 0.0 | 100.0 | NA | 0.0 | NA |
| Wilbring et al, 2013 (N=7) 33 | 0.0 | NA | 0.0 | NA | NA | 100.0 | NA | NA | NA |
Procedural and 30‐day outcomes of transcatheter mitral valve‐in‐valve replacement are shown. LVOTO indicates left ventricular outflow tract obstruction; MR, mitral regurgitation; MVC, major vascular complication; NA, not available; TA, transapical; and TS, transseptal.
*
Life‐threatening bleeding.